Trials / Completed
CompletedNCT01655082
Nicotine Patch Safety Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (actual)
- Sponsor
- Pierre Fabre Medicament · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety profile of a repeated application of a new transdermal patch compared to a reference product during 3 weeks, in a large population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | V0116 transdermal patch | One patch per day (during 24 hours) for 21 days |
| DRUG | Nicotine transdermal patch | One patch per day (during 24 hours) for 21 days |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2012-10-01
- Completion
- 2012-10-01
- First posted
- 2012-08-01
- Last updated
- 2012-12-11
Locations
4 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01655082. Inclusion in this directory is not an endorsement.